<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31228490</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN><JournalIssue CitedMedium="Internet"><Volume>168</Volume><PubDate><Year>2019</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res</ISOAbbreviation></Journal><ArticleTitle>Modifications in the branched arms of a class of dual inhibitors of HIV and EV71 replication expand their antiviral spectrum.</ArticleTitle><Pagination><StartPage>210</StartPage><EndPage>214</EndPage><MedlinePgn>210-214</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2019.06.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-3542(18)30652-1</ELocationID><Abstract><AbstractText>We have previously reported a new class of dendrimers with tryptophan (Trp) residues on the surface that show dual antiviral activities against HIV and enterovirus EV71. The prototype compound of this family is a derivative of pentaerythritol with 12 peripheral Trp groups and trivalent spacer arms. Here a novel series of dendrimers with divalent and tetravalent branched arms, instead of the trivalent ones present on the prototype, has been synthesized and its activity against HIV, EV71 and a panel of 16 different viruses and other pathogens has been determined. Convergent or divergent approaches have been used for the synthesis of these compounds. Our findings demonstrate that only compounds with tetravalent branched arms showed the same anti-HIV and anti-EV71 activity of the prototype (low micromolar) and even gain significant antiviral activity against new pathogens such as HSV-2, adenovirus-2, human corona virus and respiratory syncytial virus, being the first members of the Trp dendrimer family that showed activity against those viruses. As the prototype, these compounds also showed low-nanomolar activity against a representative EV71 clinical isolate. Experimental work carried on to determine the mode of action of the most potent IIa, containing tetravalent branched arms, demonstrated that it interacts with the viral envelopes of HIV, EV71 and HSV-2 and thus may prevent virus attachment to the host cell. These results support the interest of this new series of Trp dendrimers and qualify them as useful prototypes for the development of novel inhibitors of viral entry with broad antiviral spectrum.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mart&#xed;nez-Gualda</LastName><ForeName>Bel&#xe9;n</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Instituto de Qu&#xed;mica M&#xe9;dica (IQM-CSIC), Juan de la Cierva 3, 28006, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>KU Leuven-University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;-Mar&#xed;</LastName><ForeName>Olaia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Instituto de Qu&#xed;mica M&#xe9;dica (IQM-CSIC), Juan de la Cierva 3, 28006, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirabelli</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>KU Leuven-University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delang</LastName><ForeName>Leen</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>KU Leuven-University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neyts</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>KU Leuven-University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schols</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>KU Leuven-University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camarasa</LastName><ForeName>Mar&#xed;a-Jos&#xe9;</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Instituto de Qu&#xed;mica M&#xe9;dica (IQM-CSIC), Juan de la Cierva 3, 28006, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>San-F&#xe9;lix</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instituto de Qu&#xed;mica M&#xe9;dica (IQM-CSIC), Juan de la Cierva 3, 28006, Madrid, Spain. Electronic address: anarosa@iqm.csic.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050091">Dendrimers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>8DUH1N11BX</RegistryNumber><NameOfSubstance UI="D014364">Tryptophan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050091" MajorTopicYN="N">Dendrimers</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014364" MajorTopicYN="N">Tryptophan</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053585" MajorTopicYN="N">Virus Attachment</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014780" MajorTopicYN="N">Viruses</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AIDS</Keyword><Keyword MajorTopicYN="N">Antiviral agents</Keyword><Keyword MajorTopicYN="N">EV71</Keyword><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">HSV-2</Keyword><Keyword MajorTopicYN="N">Tryptophan</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>6</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31228490</ArticleId><ArticleId IdType="pmc">PMC7114229</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2019.06.006</ArticleId><ArticleId IdType="pii">S0166-3542(18)30652-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andries K., Dewindt B., Snoeks J., Willebrords R., Van Eemeren K., Stokbroekx R., Janssen P.A.J. In vitro activity of pirodavir (R 77975), a substituted phenoxy pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob. Agents Chemother. 1992;36:100&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189235</ArticleId><ArticleId IdType="pubmed">1317142</ArticleId></ArticleIdList></Reference><Reference><Citation>Arts E.J., Hazuda D.J. HIV-1 antiretroviral drug therapy. Cold Spring Harbor Perspect. Med. 2012;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312400</ArticleId><ArticleId IdType="pubmed">22474613</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba M., Pauwels R., Balzarini J., Arnout J., Desmyter J., De Clercq E. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. Unit. States Am. 1988;85:6132&#x2013;6136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC281919</ArticleId><ArticleId IdType="pubmed">2457906</ArticleId></ArticleIdList></Reference><Reference><Citation>Badia R., Ballana E., Est&#xe9; J.A., Riveira-Mu&#xf1;oz E. Antiviral treatment strategies based on gene silencing and genome editing. Curr. Opin. Virol. 2017;24:46&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">28437703</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Thibaut H.J., Strating J.R.P.M., van Kuppeveld F.J.M. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 2018;16:368&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Balzarini J., Laethem K.V., Daelemans D., Hatse S., Bugatti A., Rusnati M., Igarashi Y., Oki T., Schols D. Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human Immunodeficiency virus. J. Virol. 2007;81:362&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1797273</ArticleId><ArticleId IdType="pubmed">17050611</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnavas R.V., Celum C. Infectious co-factors in HIV-1 transmission Herpes Simplex Virus type-2 and HIV-1: new insights and interventions. Curr. HIV Res. 2012;10:228&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3563330</ArticleId><ArticleId IdType="pubmed">22384842</ArticleId></ArticleIdList></Reference><Reference><Citation>Barr&#xe9;-Sinoussi F., Ross A.L., Delfraissy J.-F. Past, present and future: 30 years of HIV research. Nat. Rev. Microbiol. 2013;12:877&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pubmed">24162027</ArticleId></ArticleIdList></Reference><Reference><Citation>Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antivir. Res. 2010;85:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815149</ArticleId><ArticleId IdType="pubmed">20018391</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahn P., Fink V., Patterson P. Fostemsavir: a new CD4 attachment inhibitor. Curr. Opin. HIV AIDS. 2018;13:341&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">29771694</ArticleId></ArticleIdList></Reference><Reference><Citation>De Clercq E., Li G. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 2016;29:695&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4978613</ArticleId><ArticleId IdType="pubmed">27281742</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai D.V., Kulkami S.S. Herpex simplex virus: the interplay between HSV, host and HIV-1. Viral Immunol. 2015;28:546&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">26331265</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding X., Zhu Y., Chong H., Cui S., Zhang X., He J., Wang X., He Y. Structural and functional characterization of HIV-1 cell fusion inhibitor T20. AIDS. 2018;33:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">30096076</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug resistance database 2018. https://hivdb.stanford.edu/dr-summary/resistance-notes/NNRTI/</Citation></Reference><Reference><Citation>Est&#xe9; J.A. Inhibition of HIV entry. In: De Clercq E., editor. vol. 50. Wiley-VCH Verlag GmbH&amp;Co. KGaA; Weinheim, Germany: 2011. pp. 29&#x2013;50. (Antiviral Drug Strategies, Methods and Principles in Medicinal Chemistry).</Citation></Reference><Reference><Citation>Fletcher C.V. Enfuvirtide, a new drug for HIV infection. Lancet. 2003;361:1577&#x2013;1578.</Citation><ArticleIdList><ArticleId IdType="pubmed">12747873</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulick R.M. New HIV drugs: 2018 and beyond. Curr. Opin. HIV AIDS. 2018;13:291&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">29702493</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulick R.M. Investigational antiretroviral drugs: what is coming down the pipeline. Top. Antivir. Med. 2019;25:127&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935216</ArticleId><ArticleId IdType="pubmed">29689540</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulick R.M., Flexner Ch. Long-acting HIV drugs for treatment and prevention. Annu. Rev. Med. 2019;70:137&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">30355266</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang Y., Guo J., Chen Z. Closing the door to human immunodeficiency virus. Protein Cell. 2013;4:86&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4875366</ArticleId><ArticleId IdType="pubmed">23479426</ArticleId></ArticleIdList></Reference><Reference><Citation>Klase J. The molecular basis of HIV entry. Cell Microbiol. 2012;14:1183&#x2013;1192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3417324</ArticleId><ArticleId IdType="pubmed">22583677</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari G., Singh R.K. Anti-HIV drug development: structural features and limitations of present day drugs and future challenges in the successful HIV/AIDS treatment. Curr. Pharmaceut. Des. 2013;19:1767&#x2013;1783.</Citation><ArticleIdList><ArticleId IdType="pubmed">23092282</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L., Fei Y., Lifeng C., Asim K.D., Shibo J. Development of small-molecule HIV entry inhibitors specifically targeting gp120 or gp41. Curr. To. Med. Chem. 2016;16:1074&#x2013;1090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4775441</ArticleId><ArticleId IdType="pubmed">26324044</ArticleId></ArticleIdList></Reference><Reference><Citation>Margolis A.M., Heverling H., Pham P.A., Stolbach A. A review of the toxicity of HIV medications. J. Med. Toxicol. 2014;10:26&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3951641</ArticleId><ArticleId IdType="pubmed">23963694</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Gualda B., Sun L., Rivero-Buceta E., Flores A., Quesada E., Balzarini J., Noppen S., Liekens S., Schols D., Neyts J., Leyssen P., Mirabelli C., Camarasa M.-J., San-F&#xe9;lix A. Structure-activity relationship studies on a Trp dendrimer with dual activities against HIV and enterovirus A71. Modifications on the amino acid. Antivir. Res. 2017;139:32&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">28017762</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P.C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol. Rev. 2002;26:91&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Meanwell N.A., Krystal M.R., Nowicka-Sans B., Langley D.R., Conlon D.A., Eastgate M.D., Grasela D.M., Timmins P., Wang T., Kadow J.F. Inhibitors of HIV-1 attachment: the discovery and development of Temsavir and its prodrug Fostemsavir. J. Med. Chem. 2018;61:62&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">29271653</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehellou Y., De Clercq E. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J. Med. Chem. 2010;53:521&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">19785437</ArticleId></ArticleIdList></Reference><Reference><Citation>Micewicz E.D., Ruchala P. Inhibitors of HIV-1 entry. Curr. Pharmaceut. Des. 2013;10:1784&#x2013;1799.</Citation><ArticleIdList><ArticleId IdType="pubmed">23092280</ArticleId></ArticleIdList></Reference><Reference><Citation>Munawwar A., Singh S. Human herpesviruses as copathogens of HIV infection, their role in HIV transmission, and disease progression. J. Lab. Phys. 2016;8:5&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4785766</ArticleId><ArticleId IdType="pubmed">27013807</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadel S. Hand, foot, mouth, brainstem and heart disease resulting from enterovirus 71. Crit. Care Med. 2013;41:1821&#x2013;1822.</Citation><ArticleIdList><ArticleId IdType="pubmed">23774351</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivero-Buceta E., Doyag&#xfc;ez E.G., Colomer I., Quesada E., Mathys L., Noppen S., Liekens S., Camarasa M.-J., P&#xe9;rez-P&#xe9;rez M.-J., Balzarini J., San-F&#xe9;lix A. Tryptophan dendrimers that inhibit HIV replication, prevent virus entry and bind to the HIV envelope glycoproteins gp120 and gp41. Eur. J. Med. Chem. 2015;106:34&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">26513643</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivero-Buceta E., Sun L., Mart&#xed;nez-Gualda B., Doyag&#xfc;ez E.G., Donkers K., Quesada E., Camarasa M.-J., Delang L., San-F&#xe9;lix A., Neyts J., Leyssen P. Optimization of a class of tryptophan dendrimers that inhibit HIV replication leads to a selective, specific and low-nanomolar inhibitor of clinical isolates of enterovirus A71. Antimicrob. Agents Chemother. 2016;60:5064&#x2013;5067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4958208</ArticleId><ArticleId IdType="pubmed">27246775</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas P., Holgu&#xed;n A. Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review. J. Antimicrob. Chemother. 2014;69:2032&#x2013;2042.</Citation><ArticleIdList><ArticleId IdType="pubmed">24788658</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T., Lewthwaite P., Perera D., Cardosa M.J., McMinn P., Ooi M.H. Virology, epidemiology, pathogenesis and control of enterovirus 71. Lancet Infect. Dis. 2010;10:778&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Lee H., Thibaut H.J., Rivero-Buceta E., Bator C., Martinez-Gualda B., Dallmeiera K., Delang L., Leyssen P., Gago F., San-F&#xe9;lix A., Hafenstein S., Mirabelli C., Neyts J. Viral engagement with host (co-)receptors blocked by a novel class of tryptophan dendrimers that targets the 5-fold-axis of the enterovirus-A71 capsid. PLoS Pathog. 2019;15(5) doi: 10.1371/journal.ppat.1007760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007760</ArticleId><ArticleId IdType="pmc">PMC6590834</ArticleId><ArticleId IdType="pubmed">31071193</ArticleId></ArticleIdList></Reference><Reference><Citation>Tijsma A., Franco D., Tucker S., Hilgenfeld R., Froeyen M., Leyssen P., Neyts J. The capsid binder vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. Antimicrob. Agents Chemother. 2014;58:6990&#x2013;6992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4249361</ArticleId><ArticleId IdType="pubmed">25199773</ArticleId></ArticleIdList></Reference><Reference><Citation>Tintori C., Brai A., Fallacara A.L., Fazi R., Schenone S., Botta M. Protein&#x2013;protein interactions and human cellular cofactors as new targets for HIV therapy. Curr. Opin. Pharmacol. 2014;18:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24993074</ArticleId></ArticleIdList></Reference><Reference><Citation>UNAIDS data 2018. http://www.unaids.org/en/topic/data</Citation></Reference><Reference><Citation>Vitoria M., Rangaraj A., Ford N., Doherty M. Current and future priorities for the development of optimal HIV drugs. Curr. Opin. HIV AIDS. 2019;14:143&#x2013;149. doi: 10.1097/COH.0000000000000527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/COH.0000000000000527</ArticleId><ArticleId IdType="pubmed">30562177</ArticleId></ArticleIdList></Reference><Reference><Citation>Volberding S., Deeks G. Antiretroviral therapy and management of HIV infection. Lancet. 2010;376(9734):49&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">20609987</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilen C.B., Tilton J.C., Doms R.W. Molecular mechanisms of HIV entry. Adv. Exp. Med. Biol. 2012;726:223&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">22297516</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . 2018. World Health Organization HIV/AIDS Fact Sheet [Internet]https://www.who.int/en/news-room/fact-sheets/detail/hiv-aids</Citation></Reference><Reference><Citation>Woollard S.M., Kanmogne G.D. Maraviroc: a review of its use in HIV infection and beyond. Drug Des. Dev. Ther. 2015;9:5447&#x2013;5468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4598208</ArticleId><ArticleId IdType="pubmed">26491256</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S., Yamashita Y., Li J., Hanagata N., Minowa T., Takemura T., Koike S. Scavenger receptor B2 is a celular receptor for enterovirus 71. Nat. Med. 2009;15:798&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan P., Pannecouque C., De Clercq E., Liu X. Anti-HIV drug discovery and development: current innovations and future trends. J. Med. Chem. 2016;59:2849&#x2013;2878.</Citation><ArticleIdList><ArticleId IdType="pubmed">26509831</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>